For a medical aesthetic practice to best serve its patients and maintain a viable business, it needs to understand the ways in which it may be compromising patient safety or otherwise violating the law. Therefore, if your practice has not undergone a thorough risk assessment recently, there is no time like the present.
The U.S. aesthetic neurotoxin marketplace is set to expand somewhat dramatically in 2019.
Biotechnology company Revance Therapeutics, Inc. (Newark, Calif.) recently published the results of two pivotal trials of the company's neurotoxin drug candidate DaxibotulinumtoxinA for Injection (RT002), intended for the treatment of moderate to severe glabellar lines in adults. Based on these study findings, Revance announced that it expects U.S. FDA approval in 2019 and approval in Europe in 2021.
With great regret we acknowledge the passing of Vic A. Narurkar, M.D., F.A.A.D., an internationally known, board-certified dermatologist and dermatologic surgeon from San Francisco, Calif.
Surgical rhinoplasty is one of the most popular aesthetic procedures worldwide. However, until recently, patients who wanted to avoid surgery – and the associated risks, recovery and expense – have never had a viable, non-invasive alternative that could accomplish similar cosmetic goals.
As the premier multispecialty venue for medical professionals looking to expand their aesthetic abilities, The Aesthetic Show (TAS) has firmly established itself as a progressive, first-in-class educational program covering the most cutting edge aesthetic procedures, techniques, products and technologies.
Quanta System (Samarate, Varese, Italy) has expanded its Discovery Pico (DP) Family of lasers with the addition of the new Discovery Pico DERM. The company has announced that it will introduce this new model at the upcoming AAD 2019 meeting.
Since the introduction of the picosecond laser within the aesthetic and dermatologic markets, it has become widely recognized as the safest and most effective solution for pigmented lesions and tattoo removal. Now, the PICOCARE Nd:YAG laser, developed and manufactured by Wontech, Ltd., Co. (Daejeon, South Korea), has expanded the scope of picosecond technology to treat various types of scars, skin rejuvenation and nail disorders via a variety of handpieces (595 nm and 660 nm dye handpieces and HEXA MLA).
Post-inflammatory hyperpigmentation (PIH) in Fitzpatrick skin types IV and V is the most common post-operative complication seen in this patient group. However, PIH can be avoided if appropriate modalities and settings are used.
In the medical world, the provider-patient relationship is one of shared decision making based on the principles of mutual trust, ethics and appropriate attention to needs. This guidance is of especially high value in an aesthetic practice, where the patient electively wants to achieve an enhanced appearance and improved quality of life based on physician guidance.